Skip to main content

Advertisement

SpringerLink
Log in

A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Filgrastim-sndz (Zarxio®) was approved by the FDA in March 2015 as a biosimilar product of its reference product, filgrastim (Neupogen®) for all five indications. The NCCN Clinical Practice Guidelines has incorporated filgrastim-sndz into its recommendations as a category 1 recommendation for use in settings of febrile neutropenia, myelosuppressive chemotherapy administration, and post-hematopoietic stem cell transplant (HSCT). As a cost-saving initiative, our institution switched from filgrastim to filgrastim-sndz for all indications starting in March 2016. The purpose of this study was to assess for any difference in clinical or safety outcomes between filgrastim and filgrastim-sndz. This is an IRB-approved, single institution, 1-year retrospective chart review (September 2015 to August 2016) conducted in hospitalized adults who received either filgrastim or filgrastim-sndz either for prophylaxis of chemotherapy-induced myelosuppression or for neutrophil recovery after autologous HSCT. Our data showed no differences in duration of G-CSF therapy (7.96 vs. 8.5 days, P = 0.36), white blood count (WBC) (8.99 vs. 8.04, P = 0.28), absolute neutrophil count (ANC) (7.62 vs. 6.91 × 109/L, P = 0.36) at the time of granulocyte-colony stimulating factor (G-CSF) discontinuation, or safety of filgrastim and filgrastim-sndz. The efficacy and safety of filgrastim and filgrastim-sndz were similar for prophylaxis of chemotherapy-induced neutropenia and neutrophil recovery post-autologous HSCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maschmeyer G, Rolston K. Myeloid growth factors. Infections in Hematology. Springer Berlin Heidelberg: 2015

  2. Nahon S et al (2016) Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicenter study. Support Care Cancer 24:1991–1998

    Article  PubMed  Google Scholar 

  3. Elayan MM et al (2015) Tbo-filgrastim versus filgrastim during mobilization and neutrophil engraftment for autologous stem cell transplantation. Biol Blood Marrow Transplant 21:1921–1925

    Article  CAS  PubMed  Google Scholar 

  4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: myeloid growth factors. Version 1.2017. NCCN.org

  5. Renwick W, Pettengell R, Green M (2009) Use of filgrastim and pegfilgrastim to support delivery of chemotherapy. BioDrugs 23:175–186

    Article  CAS  PubMed  Google Scholar 

  6. Hirsch BR, Lyman GH (2013) Will biosimilars gain momentum? J Natl Compr Cancer Netw 11:1291–1297

    Article  CAS  Google Scholar 

  7. Sorgel F et al (2015) Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. BioDrugs 29:123–131

    Article  PubMed  PubMed Central  Google Scholar 

  8. Zelenetz AD (2016) The role of biosimilars. J Natl Compr Cancer Netw 14(5):626–629

    Article  CAS  Google Scholar 

  9. Blackstone EA, Fuhr JP Jr (2012) Innovation and competition: will biosimilars succeed? Biotechnol Healthc 9:24–27

    PubMed  PubMed Central  Google Scholar 

  10. Awad M et al (2017) Zarxio (filgrastim-sndz): the first biosimilar approved by the FDA. PT 42:19–23

    Google Scholar 

  11. Blackwell K et al (2015) Comparison of EP2006, a filgrastim biosimilar, to the reference: phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol 26(9):1948–1953. https://doi.org/10.1093/annonc/mdv281

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Harada K et al (2016) Comparison of transplant outcomes and economic costs between biosimilar and originator filgrastim in allogeneic hematopoietic stem cell transplantation. Int J Hematol 104:709–719

    Article  CAS  PubMed  Google Scholar 

  13. Yoshimura H et al (2017) Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation. J Blood Med 8:5–12

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, The Mount Sinai Hospital, One Gustave L. Levy Place, Box 1211, New York, NY, 10029-6574, USA

    Julia Zecchini, Kendra Yum & Sara Kim

  2. Division of Hematology/Oncology, Tisch Cancer Institute, New York, NY, USA

    Amir Steinberg & Cardinale Smith

Authors
  1. Julia Zecchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kendra Yum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amir Steinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cardinale Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sara Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia Zecchini.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zecchini, J., Yum, K., Steinberg, A. et al. A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation. Support Care Cancer 26, 1013–1016 (2018). https://doi.org/10.1007/s00520-017-3923-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-017-3923-1

Keywords

Search

Navigation